Compare Summit Therapeutics Inc (SMMT) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Synopsys, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Synopsys, Inc. trades at $509.99 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 7× Summit Therapeutics Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Synopsys, Inc. for 71 Days on average.
| SMMT | SNPS | |
|---|---|---|
Market Cap | $13.71B | $95.39B |
Volume | 6,173,057 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $26.38 | $534.56 |
52-Week Low | $12.43 | $367.70 |
Typical Hold Time | 16 Days | 71 Days |
Enterprise Value | $13.04B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Synopsys (SNPS) trades at $497.75, down 0.98% on the day, but maintains strong momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Recent AI partnerships with OpenAI and Amazon, along with raised 2027 guidance, have driven significant investor optimism and a 13% surge in early October 2026.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus price target representing 15% upside. Key risks include high valuation multiples (P/E 86.87) and integration challenges from the Ansys acquisition. Revenue growth acceleration to $9.4B projected for 2026 and expanding AI-driven chip design opportunities support the bullish case, though investors should monitor execution on ambitious growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
